Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Very Bullish +85

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

Company update Drug approval Product launch AI-generated analysis

πŸ“ˆ Eli Lilly holds a 61% market share in the U.S. GLP-1 space as of Q2, significantly ahead of rival Novo Nordisk's 39%.

πŸ’Š Foundayo is gaining rapid ground in the oral weight loss market, with one-third of new pill patients currently taking Lilly's drug.

πŸ‘΄ Lilly dominates the Medicare obesity market, capturing 70% of new GLP-1 prescriptions among seniors since coverage began in July.

πŸš€ Zepbound remains a key driver for Lilly, offering higher efficacy than original Wegovy doses and securing dominance in injectables.

πŸ”¬ Retatrutide is expected to receive approval in Q1 2027, representing a triple-agonist with superior weight loss results in trials.

πŸ’‰ A new weekly injection targeting the amylin receptor is in development to address patients who do not tolerate current GLP-1s.

🏭 Foundayo's small-molecule structure allows for easier and more cost-effective manufacturing at scale compared to Novo's peptide drugs.

πŸ“Š Analyst Leerink Partners expects Foundayo to eventually dominate the global oral GLP-1 market due to Lilly's commercial firepower.

πŸ” CagriSema from rival Novo showed mixed results in head-to-head trials, with lower doses showing less efficacy than Zepbound's active ingredient.

πŸ“ˆ Lilly's pipeline includes novel candidates designed to extend its lead beyond current best-sellers as patent expirations approach.

Bullish Signals
  • Eli Lilly holds a commanding 61% market share in the U.S. GLP-1 space, significantly outpacing rival Novo Nordisk which holds only 39%.
  • The company's new oral drug Foundayo is capturing one-third of all new GLP-1 pill patients, demonstrating rapid adoption and commercial success.
  • Lilly dominates the Medicare obesity market with 70% of new senior prescriptions following the start of coverage in July.
  • Zepbound continues to drive growth with higher efficacy than initial Wegovy doses, helping Lilly maintain its lead in the injectable segment.
  • Analysts highlight Lilly's 'tremendous commercial firepower' and global initiative as key advantages that sustain its leadership position.
  • The upcoming approval of retatrutide in Q1 2027 promises a triple-agonist drug with superior weight loss results compared to existing treatments.
  • Foundayo's small-molecule structure enables more cost-effective and scalable manufacturing than Novo's peptide-based competitors like Wegovy.
Full Analysis
Eli Lilly continues to solidify its dominant position in the global obesity drug market, particularly as rival Novo Nordisk faces investor skepticism regarding its growth strategy. In the burgeoning oral GLP-1 space, Lilly's new drug Foundayo is gaining significant traction, with CEO Dave Ricks reporting that one-third of new pill patients are already taking the company's medication. This momentum extends to the Medicare market, where 70% of seniors initiating GLP-1 therapy in July were prescribed Lilly's drugs, reinforcing its status as the dominant player in both injectable and oral segments. Lilly maintains a substantial lead over Novo Nordisk in the overall U.S. GLP-1 space, holding approximately 61% market share in the second quarter compared to Novo's 39%. The company's primary driver remains Zepbound, an injectable drug with higher efficacy than initial Wegovy doses, which has helped secure its dominance despite Novo launching a higher-dose version of its own injection. Analysts highlight Lilly's 'tremendous commercial firepower' and global initiative as key advantages that allow it to maintain its leadership while competitors struggle to match its scale and manufacturing capacity. Looking forward, Lilly is leveraging its advanced pipeline to extend its lead beyond current best-sellers. The company plans to seek approval for retatrutide, a triple-agonist drug showing superior weight loss in clinical trials, by the first quarter of 2027. Additionally, Lilly is developing a weekly injection targeting the amylin receptor, a pathway distinct from existing treatments, which analysts believe has significant potential given that many patients do not tolerate current GLP-1 drugs. These next-generation assets position Lilly to sustain growth even as patent expirations for competitors' core products approach. Despite the competitive pressure, Lilly's strategy focuses on high-efficacy injectables and scalable oral options that offer convenience without compromising efficacy. While Novo Nordisk is pivoting toward a fragmented market with multiple new drug candidates to replace its mega-blockbuster franchise, Lilly is capitalizing on its established supply chain and commercial strength. The company's ability to manufacture small-molecule drugs like Foundayo more easily at scale than peptide-based competitors further enhances its long-term competitive moat in the obesity treatment landscape.